Interview: Jean-Marc Juteau, Director, Biotech City, Canada
The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government…
Halo Pharma’s capabilities in the areas of tech transfer, process and pharmaceutical product development, formulation development, production, scale-up and validation, and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. Our expertise across many dosage forms, including complex oral solids, topicals, oral solutions and suspensions and the manufacture of controlled substances is unmatched in North America. Halo Pharma serves a growing global customer base across multiple regulatory environments. These attributes allow Halo Pharma to be a partner of choice for many of today’s large pharma, generic pharma and biotech pharma companies.
Contact:
Address: 17800 Lapointe Street, Mirabel, QC J7J 1P3, Canada
Tel.: +1 450 433 7673
Website: https://www.halopharma.com/
The director of Biotech City in Laval, close to Montreal, discusses the advantages brought on by the cluster effect, and how this has played out at Biotech City, a government…
The head of Lundbeck in Canada talks about the stigma of mental illness that still exists in the country today, and how CNS companies like Lundbeck are working with stakeholders…
Industry veteran and CEO of JSS Medical research explains what he thinks is going wrong with clinical research in Canada today, how Canadian CROs are losing out at the hands…
As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country, talks about the desperate…
An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a company dedicated to bringing…
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto’s best research institutions and supported by the government, assesses Toronto’s merits as an innovation hub, and describes…
Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state an attractive place for…
A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and approval processes, removing duplication…
The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an association in Quebec that…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector…
See our Cookie Privacy Policy Here
